Board of Directors

MICHAEL HEFFERNAN

Founder, President, CEO

Michael Heffernan is the Founder, President and CEO of Collegium Pharmaceutical, Inc. He has more than 25 years of experience in the pharmaceutical and related healthcare industries. He was previously the Founder, President and CEO of Onset Dermatologics, a dermatology focused company that was spun out of Collegium to create PreCision Dermatology and was sold to Valeant (2014). Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp and later served as President and CEO of PhyMatrix. Michael began his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been an advisor and Investor in a number of healthcare companies. His past board memberships include; TyRx (sold to Medtronic), Cornerstone Therapeutics (sold to Chiesi), Ocata (sold to Astellas), and PreCision Dermatology. Michael is currently the Chairman of the board for Veloxis Pharmaceuticals (OMX:VELO) and serves on the board for Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX). Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.

GAREN BOHLIN

Garen Bohlin held senior executive positions with biotechnology companies for almost 30 years. In his final operating role, Garen was Executive Vice President of Constellation Pharmaceuticals. Previously, he served as Chief Operating Officer of Sirtris Pharmaceuticals, which was acquired by GlaxoSmithKline. Prior to Sirtris, he was President and Chief Executive Officer of Syntonix Pharmaceuticals, which was acquired by Biogen Idec. Prior to Syntonix, he was Executive Vice President of Genetics Institute, which was acquired by American Home Products/Wyeth. Garen played a key strategic role in each of his positions and also had substantial operational experience. Mr. Bohlin currently serves on the board of directors of Karyopharm Therapeutics Inc., Proteon Therapeutics, Inc. and Tetraphase Pharmaceuticals, Inc. and previously served as a director on the boards of five other companies.

JOHN A. FALLON, M.D.

Dr. Fallon served as Senior Vice President and Chief Physician Executive at Blue Cross Blue Shield of Massachusetts (“BCBS”) from 2004 through 2015. Prior to his role at BCBS, Dr. Fallon served as Chief Executive Officer for clinical affairs at the State University of New York Downstate Medical Center. His professional experience includes the Partners Healthcare System, where he was Chairman of the physician network. Dr. Fallon was also the CEO of Charter Professional Services Corporation and the founder and CEO of North Shore Health System. He serves as the lead independent director on the board of directors of Insulet Corporation (NASDAQ: PODD), and as a member of the boards of directors of Exact Sciences Corporation (NASDAQ: EXAS), and AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG). Dr. Fallon is Chairman of the board of directors of NEHI (Network for Excellence in Health Innovation). In the past, he also served as a member of several not-for-profit boards, including: Alliance for Healthcare Improvement, Massachusetts Health Quality Partners, Massachusetts E-Health Collaborative and Neighborhood Health Plan. Dr. Fallon practiced internal medicine for more than 25 years, fulfilled his residency at Boston City Hospital, and is Board Certified in Internal Medicine. He received a B.A. from the College of the Holy Cross, an M.B.A. from the University of South Florida and a M.D. from Tufts University School of Medicine.

JOHN G. FREUND, M.D.

John G. Freund, M.D. co-founded Skyline Ventures in 1997 and has served as a partner at Skyline since its founding. Prior to joining Skyline, Dr. Freund served as managing director in the private equity group of Chancellor Capital Management, a private capital investment firm. In 1995, he co-founded Intuitive Surgical, a medical device company, and served on its board of directors until 2000. From 1988 to 1994, Dr. Freund served in various positions at Acuson Corporation, a maker of ultrasound equipment that is now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, Dr. Freund was a general partner at Morgan Stanley & Co., an investment banking company, where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. He has served on the board of directors of XenoPort, Inc., a publicly traded biopharmaceutical company, since 1999, and Tetraphase Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since 2012. Dr. Freund also serves on the board of directors of two privately held companies, Advion and DiscoverX, and three U.S. registered investment funds managed by Capital Research and Management. He also previously served on the board of directors of four publicly traded companies, Map Pharmaceuticals, a biopharmaceutical company, Hansen Medical, a biotechnology company, Sirtris Pharmaceuticals, a biopharmaceutical company, and Mako Surgical Corp., a medical device company. Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative, and is a member of the Therapeutics Advisory Council of Harvard Medical School. Dr. Freund received a B.A. in history from Harvard College, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School.

DAVID HIRSCH, Ph.D., M.D.

David Hirsch is a founder and Managing Director of Longitude Capital where he focuses on investments in biotechnology. From 2005 to 2006, Dr. Hirsch was a Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization and managed care strategy. In addition to serving on the Board of Collegium Pharmaceutical, Inc., he also serves on the boards of Civitas Therapeutics and Precision Therapeutics and is a board observer at InfaCare Pharmaceuticals and Xanodyne Pharmaceuticals. He is also actively involved with Longitude’s investments in Amarin (NASDAQ: AMRN) and Corcept Therapeutics (NASDAQ: CORT), as well as prior investments in Horizon Therapeutics and Sequenom (NASDAQ: SQNM). Dr.Hirsch holds a Ph.D. in Biology from the Massachusetts Institute of Technology, and M.D. from Harvard Medical School and a B.A. in Biology from The Johns Hopkins University.

GWEN A. MELINCOFF

Gwen Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries.  Ms. Melincoff is currently managing director at Gemini Advisors LLC and an advisor to Phase 1 Ventures and Verge Genomics.  From August 2014 to September 2016, she served as Vice President of Business Development at BTG International Inc., a UK-specialist healthcare company.  From September 2004 to the December 2013, Ms. Melincoff was Senior Vice President of Business Development at Shire Plc.  In addition, from 2010 to 2013, she led the Shire Strategic Investment Group, the venture capital arm of Shire Plc.  Prior to joining Shire Plc, Ms. Melincoff held managerial and business development positions at various pharmaceutical companies, such as Adolor Corporation. Ms. Melincoff currently serves on the boards of Kamada Ltd. (Nasdaq: KMDA) and Photocure ASA.  Previously, she served as a board member or observer on the boards of Tobira Therapeutics (acquired by Allergan), DBV Technologies, AM Pharma, ArmaGen Technologies, Promethera Biosciences, Naurex Inc. (acquired by Allergan) and Enterome.  Ms. Melincoff holds a B.S. in Biology from The George Washington University and an M.S. in Management and Health Care Administration from Pennsylvania State University.  Ms. Melincoff has also attained the designation of Certified Licensing Professional (CLP™).  Ms. Melincoff was named a “Top Women in Biotech 2013” by Fierce Biotech as well as being named to the Powerlist 100 of Corporate Venture Capital in 2012 and 2013.

GINO SANTINI

Gino Santini is a senior advisor providing financing and business consulting services to venture capital, pharmaceutical and biotech companies. He currently serves on the boards of AMAG Pharmaceuticals (NASDAQ: AMAG), Horizon Pharma (NASDAQ: HZNP) and Allena Pharmaceuticals. He retired as Senior Vice President of Corporate Strategy and Business Development of Eli Lilly in December 2010, after a career with the company of over 27 years. He had held the position since 2007, and had became a member of the company’s Executive Committee reporting to the CEO since January 2004. Previously, he had served as President of US Operations since 1999, with full P/L responsibility and sales in the US market of over $7 Billion in 2004.

Mr. Santini was born in Cesena, Italy. He received a degree in mechanical engineering from the University of Bologna, Italy, in 1981 and a Master of Business Administration degree from the University of Rochester in 1983. He joined Lilly in 1983 as a financial planning associate in Italy and has held various positions in the financial and marketing components in Italy and Indianapolis. In 1990, Santini was appointed Pharmaceutical Director for the Lilly affiliate in Belgium, and in 1991, he was named General Manager of Eli Lilly Compania de Mexico in Mexico City. He served as Area Director of Latin America from 1994 to 1995. In 1995, he became Vice President of Corporate Strategy and Business Development with the responsibility for the Public Policy and Development Group added in early 1996. He was named President of the Women’s Health Business Unit in 1997.

Mr. Santini is a past Chairman of the Board of the National Pharmaceutical Council and of Noble of Indiana, a nonprofit agency serving individuals with developmental disabilities in Central Indiana. He also served on the Board of Directors of the United Way of Central Indiana and the Executive Committee and Board of the Indianapolis Chamber of Commerce. He is an Italian citizen and lives with his family in the United States.

THEODORE SCHROEDER

Theodore Schroeder is the President, CEO, Director and co-founder of Zavante Therapeutics, Inc., a private biopharmaceutical company. Previously, Mr. Schroeder co-founded Cadence Pharmaceuticals, Inc., and served as its President and Chief Executive Officer, and as a member of the board of directors, from May 2004 until its acquisition in May 2014 by Mallinckrodt Pharmaceuticals, Inc. Prior to co-founding Cadence he held several roles at Elan Pharmaceuticals, including senior vice president of North America sales and marketing and vice president and general manager of the Hospital Products Business Unit, a role he also held at Dura Pharmaceuticals before its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb. Mr. Schroeder currently serves on the board of Cidara Therapeutics (Nasdaq:CDTX) and Otonomy, Inc., (Nasdaq: OTIC). Mr. Schroeder previously served on the boards of Hyperion Therapeutics, Incline Therapeutics and Trius Therapeutics until their respective acquisitions. Mr. Schroeder is a member of the Sharp Hospital Foundation board and chair of the BIOCOM board of directors. He holds a bachelor’s degree in management from Rutgers University.